CD19 Antibody (FMC63) [PE]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-52716PE
Recombinant Monoclonal Antibody. Clone FMC63 was used by HLDA to establish CD designation.
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
CyTOF-ready, ELISA, Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin
Label
PE (Excitation = 488 nm, Emission = 575 nm)
Antibody Source
Recombinant Monoclonal Mouse IgG2a Kappa Clone # FMC63
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for CD19 Antibody (FMC63) [PE]
Immunogen
Human prolymphocytic leukaemia cell line JVM3.
Reactivity Notes
Human
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2a Kappa
Scientific Data Images for CD19 Antibody (FMC63) [PE]
Product Image: CD19 Antibody (FMC63) [PE] [NBP2-52716PE] - Vial of PE conjugated antibody. PE has two excitation maxima, 498 nm excited by the Blue laser (488 nm) and 565 nm excited by the Yellow-Green laser (561 nm). Both result in emission at 578 nm.
Applications for CD19 Antibody (FMC63) [PE]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry
Optimal dilutions of this antibody should be experimentally determined.
Immunohistochemistry-Paraffin
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
PBS
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CD19
Considering the role of CD19 in BCR signaling and its expression in development from pre-B cells through plasma cells, it is understandable that CD19 dysfunction and abnormal expression is associated with numerous B cell malignancies and autoimmune disorders (1-5). CD19 expression is typically observed at relatively normal levels in B cell acute lymphoblastic leukemia (B-ALL) and chronic lymphoblastic leukemia (CLL) but is often reduced other types of lymphoma including diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) (1,2). On the other hand, CD19 expression is typically increased in autoimmune disorders such as systemic sclerosis (SSc) and multiple sclerosis (MS) as modeled by experimental autoimmune encephalomyelitis (EAE) (2). CD19 has become a therapeutic molecular target for the treatment of B cell lymphomas and autoimmune disorders using monoclonal antibodies (mAbs), bi-specific T cell engaging (BiTE) antibodies, and CD19-specific chimeric antigen receptor (CAR) T cells (1,2,4-6). Although anti-CD19 CAR T cell therapy has become the standard for the treatment of B cell malignancies, patients may experience relapse due to resistance mechanisms (6). Strategies to improve efficacy and limit relapse include combination of CAR T cell therapy with immune checkpoint inhibitors like anti-PD-1 (4,6).
References
1. Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36. https://doi.org/10.1186/2162-3619-1-36
2. Li X, Ding Y, Zi M, et al. CD19, from bench to bedside. Immunol Lett. 2017;183:86-95. https://doi.org/10.1016/j.imlet.2017.01.010
3. Wentink MWJ, van Zelm MC, van Dongen JJM, Warnatz K, van der Burg M. Deficiencies in the CD19 complex. Clin Immunol. 2018;195:82-87. https://doi.org/10.1016/j.clim.2018.07.017
4. Frigault MJ, Maus MV. State of the art in CAR T cell therapy for CD19+ B cell malignancies. J Clin Invest. 2020;130(4):1586-1594. https://doi.org/10.1172/JCI129208
5. Penack O, Koenecke C. Complications after CD19+ CAR T-Cell Therapy. Cancers (Basel). 2020;12(11):3445. https://doi.org/10.3390/cancers12113445
6. Bouziana S, Bouzianas D. Anti-CD19 CAR-T cells: Digging in the dark side of the golden therapy. Crit Rev Oncol Hematol. 2021;157:103096. https://doi.org/10.1016/j.critrevonc.2020.103096
Alternate Names
CD19, CVID3, Leu-12
Gene Symbol
CD19
Additional CD19 Products
Product Documents for CD19 Antibody (FMC63) [PE]
Product Specific Notices for CD19 Antibody (FMC63) [PE]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...